LncRNA-mRNA Co-Expression Analysis Identifies AL133346.1/CCN2 as Biomarkers in Pediatric B-Cell Acute Lymphoblastic Leukemia.
LncRNA-mRNA Co-Expression Analysis Identifies AL133346.1/CCN2 as Biomarkers in Pediatric B-Cell Acute Lymphoblastic Leukemia.
复制标题
LncRNA-mRNA共表达分析作为儿科B细胞急性淋巴细胞白血病的生物标志物的MANUAL 133346.1/CCN 2。
DOI:
10.3390/cancers12123803
复制
发表时间:
2020-12-17
期刊:
影响因子:
5.2
通讯作者:
Medina PP
中科院分区:
文献类型:
--
作者:
Cuadros M;García DJ;Andrades A;Arenas AM;Coira IF;Baliñas-Gavira C;Peinado P;Rodríguez MI;Álvarez-Pérez JC;Ruiz-Cabello F;Camós M;Jiménez-Velasco A;Medina PP
Dysregulation of noncoding RNAs has been described in numerous types of cancers and it has been associated with oncogenic or tumor suppressor activities. However, the signature of clinically relevant noncoding RNAs in pediatric B-cell acute lymphoblastic leukemia is still poorly understood. In a search for long non-coding RNAs that characterize pediatric B-cell acute lymphoblastic leukemia, we found that the long non-coding RNA AL133346.1 and a neighbouring protein-coding mRNA (CCN2) were significantly over-expressed in leukemia samples compared to healthy bone marrow. Survival analysis showed that patients with high CCN2 expression had a significantly better prognosis. These data suggest that AL133346.1/CCN2 could be useful for discriminating subtypes of leukemia and that CCN2 expression could predict the prognosis of pediatric patients with B-cell acute lymphoblastic leukemia. Pediatric acute B-cell lymphoblastic leukemia (B-ALL) constitutes a heterogeneous and aggressive neoplasia in which new targeted therapies are required. Long non-coding RNAs have recently emerged as promising disease-specific biomarkers for the clinic. Here, we identified pediatric B-ALL-specific lncRNAs and associated mRNAs by comparing the transcriptomic signatures of tumoral and non-tumoral samples. We identified 48 lncRNAs that were differentially expressed between pediatric B-ALL and healthy bone marrow samples. The most relevant lncRNA/mRNA pair was AL133346.1/CCN2 (previously known as RP11-69I8.3/CTGF), whose expression was positively correlated and increased in B-ALL samples. Their differential expression pattern and their strong correlation were validated in external B-ALL datasets (Therapeutically Applicable Research to Generate Effective Treatments, Cancer Cell Line Encyclopedia). Survival curve analysis demonstrated that patients with “high” expression levels of CCN2 had higher overall survival than those with “low” levels (p = 0.042), and this gene might be an independent prognostic biomarker in pediatric B-ALL. These findings provide one of the first detailed descriptions of lncRNA expression profiles in pediatric B-ALL and indicate that these potential biomarkers could help in the classification of leukemia subtypes and that CCN2 expression could predict the survival outcome of pediatric B-cell acute lymphoblastic leukemia patients.
登录
查看更多内容
影响因子:
14.9
作者:
Kuleshov MV;Jones MR;Rouillard AD;Fernandez NF;Duan Q;Wang Z;Koplev S;Jenkins SL;Jagodnik KM;Lachmann A;McDermott MG;Monteiro CD;Gundersen GW;Ma'ayan A
通讯作者:
Ma'ayan A
影响因子:
12.3
作者:
Marchese FP;Raimondi I;Huarte M
通讯作者:
Huarte M
影响因子:
16.6
作者:
Gandhi, Minakshi;Gross, Matthias;Diederichs, Sven
通讯作者:
Diederichs, Sven
影响因子:
16
作者:
Paralkar VR;Taborda CC;Huang P;Yao Y;Kossenkov AV;Prasad R;Luan J;Davies JO;Hughes JR;Hardison RC;Blobel GA;Weiss MJ
通讯作者:
Weiss MJ
影响因子:
--
作者:
Ghazavi F;De Moerloose B;Van Loocke W;Wallaert A;Helsmoortel HH;Ferster A;Bakkus M;Plat G;Delabesse E;Uyttebroeck A;Van Nieuwerburgh F;Deforce D;Van Roy N;Speleman F;Benoit Y;Lammens T;Van Vlierberghe P
通讯作者:
Van Vlierberghe P